Skip to main content
Premium Trial:

Request an Annual Quote

Enzo, Hologic, Grifols Settle Patent Dispute

NEW YORK (GenomeWeb) – Enzo Life Sciences has entered into a settlement and license agreement with Hologic, Grifols, and Grifols Diagnostic Solutions, Enzo disclosed in a recent filing with the US Securities and Exchange Commission.

The agreement settles all outstanding patent disputes among the parties and includes a one-time payment of $14 million to Enzo in exchange for fully paid-up, worldwide licenses to Hologic and Grifols, according to the SEC document.

The dispute centered on Enzo's US Patent No. 6,221,581, covering modified nucleotides for use in diagnostic and therapeutic applications.

In its SEC filing, Enzo said that the settlement and license agreement should not be considered an admission of liability or responsibility, or lack thereof, on the part of Enzo, Hologic, or Grifols. 

In 2017, Enzo had announced that one of its patents at the center of a long-running intellectual property dispute has been found invalid by a federal judge.

Enzo originally sued several companies for allegedly infringing some of its patents. A handful of defendants settled with Enzo in recent years, while others sought to have Enzo's patents invalidated.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.